Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal solid malignancies, characterised by rising incidence, poor long-term survival, and profound resistance to systemic therapy. Its poor prognosis reflects late diagnosis, early metastati...
Background/Objectives: Gestational choriocarcinoma is an uncommon neoplasia related to pregnancy. Signs and symptoms remain unspecific, while abnormal uterine bleeding is the main symptom. Methods: We report a case of a 40-year-old woman with gestati...
Immune checkpoint inhibitors (ICIs) have translated the scope of cancer therapy, but their immune-restorative mechanism can lead to immune-related adverse events (irAEs), which can affect several organs with varying severity. Early identification of...
Macroautophagy is a key adaptive process that enables tumour cells to withstand the cytotoxic stress induced by standard antitumour treatments, thereby contributing to therapeutic resistance. In this context, identifying regulators capable of modulat...
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy, with rising incidence and a 5-year survival rate of 13%. Late presentation, early metastasis, and intrinsic resistance constrain the efficacy of cytotoxic chemotherapy, which rema...
Background/Objectives: Prostate cancer (PCa) incidence is rising, with radical prostatectomy (RP) as the main curative surgery for localised cases, which includes removing seminal vesicles (SV). SV invasion (SVI) predicts poor oncological outcomes, m...
Background/Objectives: The anti-CLDN18.2 antibody zolbetuximab has emerged as a novel therapeutic option for advanced gastric adenocarcinoma. However, robust predictive biomarkers for its efficacy remain an unmet need. Methods: Utilizing the Japanese...
Prostate cancer (PCa) is a prevalent malignancy in men worldwide, and both androgen deprivation therapy (ADT) and radiotherapy (RT) are key components of its management. However, these treatments significantly affect bone health by inducing bone mine...
Rationale: Radium-223 dichloride (223RaCl2) is an FDA-approved alpha-emitting radiopharmaceutical that targets bone metastases in metastatic castration-resistant prostate cancer (mCRPC). This study investigates the therapeutic and immunological effec...
Undifferentiated melanoma (UM) is a rare and diagnostically challenging subtype of malignant melanoma that often lacks traditional histological features and immunophenotypic expression. We report the case of a 58-year-old man with a history of a prev...
It is with great honor and satisfaction that I write this introductory Editorial for the launch of Precision Oncology, focused on a transformational discipline in the field of precision medicine for cancer [...]
Background/Objectives: Radioactive iodine (RAI) therapy is widely used to treat metastatic differentiated thyroid cancer. To investigate physiological determinants of treatment response, a mechanistic model was developed, formulated as a system of co...
Background and Clinical Significance: Inflammatory myofibroblastic tumors (IMTs) are rare neoplasms with low metastatic potential but a high recurrence rate. Approximately 60–80% of IMTs harbor anaplastic lymphoma kinase (ALK) gene rearrangemen...
